NCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
Clinical Trials
64 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT01378975 2025-06-25
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT02145910 2025-05-02
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
Phase 1 Withdrawn
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03625141 2024-04-11
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT03430947 2023-09-14
RadioCoBRIM
Technische Universität Dresden
Phase 2 Terminated
NCT05263453 2023-05-31
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT01657591 2023-01-19
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02052193 2022-12-19
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
Phase 2 Terminated
NCT02414750 2022-11-30
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Terminated
NCT02036086 2022-10-27
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Phase 2 Unknown
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT01959633 2022-02-24
VEMUPLINT
Fondazione Melanoma Onlus
Phase 1/2 Completed
NCT02818023 2022-01-03
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
University of Pittsburgh
Phase 1 Terminated
NCT01638676 2021-10-29
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
University of Louisville
Phase 1/2 Recruiting
NCT03224208 2021-04-26
VECODUE
Fondazione Melanoma Onlus
Phase 2 Terminated
NCT01597908 2021-02-24
COMBI-v
Novartis
Phase 3 Completed
NCT02303951 2021-02-03
NEO-VC
University Hospital Tuebingen
Phase 2 Terminated
NCT01683188 2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4 Terminated
NCT01942993 2020-09-30
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01512251 2020-08-17
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
University of California, San Francisco
Phase 1/2 Completed
NCT01656642 2020-07-21
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
Phase 1 Completed
NCT01897116 2020-05-29
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02354690 2020-03-23
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT02608034 2020-02-12
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Genentech, Inc.
Phase 1 Completed
NCT01898585 2020-01-07
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 4 Completed
NCT01585415 2019-11-21
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02768207 2019-08-28
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01271803 2019-07-29
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01667419 2019-07-23
BRIM8
Hoffmann-La Roche
Phase 3 Completed
NCT01910181 2019-05-29
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01813214 2019-02-26
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
Phase 2 Terminated
NCT02068079 2019-01-30
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Duke University
Phase 1 Withdrawn
NCT03139513 2019-01-22
MELANIS
Hoffmann-La Roche
Completed
NCT02050321 2018-12-26
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
University of Arizona
Phase 2 Terminated
NCT01673854 2018-07-24
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT01943422 2018-04-03
12-107
University of Pittsburgh
Phase 1 Completed
NCT02441465 2017-11-14
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT01495988 2017-10-24
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Phase 2 Terminated
NCT00405587 2017-08-22
Safety Study of PLX4032 in Patients With Solid Tumors
Plexxikon
Phase 1 Completed
NCT00949702 2017-07-25
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01586195 2017-05-25
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Genentech, Inc.
Phase 2 Terminated
NCT01843738 2017-05-24
Radiation Use During Vemurafenib Treatment
University of Utah
Phase 1 Withdrawn